870459-75-9

Upstream product

• 870459-74-8 1-(4-tert-butyl-phenyl)-3-hydroxy-5-methoxy-1H-indole-2-carboxylic acid ethyl ester 
• 911829-76-0 1-(4-tert-butyl-phenyl)-5-methoxy-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester 

Downstream Products

• 911847-10-4 1-(4-tert-butyl-phenyl)-3-(3-trifluoromethyl-phenoxy)-5-(4-trifluoromethyl-pyridin-2-yloxy)-1H-indole-2-carboxylic acid ethyl ester 
• 911847-06-8 1-(4-tert-butyl-phenyl)-5-(pyridin-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester 
• 911838-69-2 1-(4-tert-butyl-phenyl)-5-isobutoxy-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester 
• 911838-50-1 1-(4-tert-butyl-phenyl)-5-ethoxy-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester 
• 911847-15-9 1-(4-tert-butyl-phenyl)-5-(4-chloro-pyridin-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists

A series of novel aryl indole-2-carboxylic acids has been identified as potent selective PPARγ modulators. Their chemical synthesis and in vitro activities are discussed. Compound 5 was selected for in vivo testing in the db/db mouse model of type 2 diabetes and resulted in reduction of hyperglycemia at comparable plasma exposure when compared to rosiglitazone.